Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
The Fast & Furious energy hits a new level. In this milestone episode, the custom trunk fabrication takes shape alongside a ...
The Autopian on MSN
Some Geniuses Are Installing Jeep Gladiator Parts On Old Jeep Comanches
When the Jeep Gladiator debuted at the 2018 Los Angeles Auto Show, it sparked a renewed interest in the Jeep pickup that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback